Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 341,953
  • Shares Outstanding, K 15,064
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,470 K
  • 60-Month Beta 2.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.93
Trade JSPR with:

Options Overview Details

View History
  • Implied Volatility 116.39% ( -19.66%)
  • Historical Volatility 52.83%
  • IV Percentile 42%
  • IV Rank 13.89%
  • IV High 722.53% on 12/19/23
  • IV Low 18.58% on 01/05/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 143
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 2,444
  • Open Int (30-Day) 2,365

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.09
  • Number of Estimates 6
  • High Estimate -0.96
  • Low Estimate -1.19
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +27.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.11 +18.79%
on 06/26/24
26.83 -15.41%
on 06/06/24
-1.28 (-5.34%)
since 05/28/24
3-Month
19.11 +18.79%
on 06/26/24
31.01 -26.80%
on 04/01/24
-6.66 (-22.68%)
since 03/28/24
52-Week
4.00 +467.50%
on 12/13/23
31.01 -26.80%
on 04/01/24
+9.20 (+68.15%)
since 06/28/23

Most Recent Stories

More News
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 68.61 (-0.32%)
AMGN : 312.45 (-0.40%)
BMY : 41.53 (+0.05%)
NVS : 106.46 (-0.08%)
BGNE : 142.67 (-2.00%)
JSPR : 22.70 (+3.13%)
VIGL : 4.00 (-10.71%)
ALVR : 0.7233 (-7.27%)
RCUS : 15.23 (+0.40%)
FLACU : 9.50 (+2.48%)
S&P Futures Tick Lower As Investors Await Fed Rate Decision, Snap Plunges on Weak Outlook

March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices finished the regular session higher as market participants weighed up economic data and a slew...

ESH23 : 3,957.05s (-0.09%)
GM : 46.46 (+1.93%)
PHM : 110.10 (+0.32%)
SNAP : 16.61 (+0.24%)
HUSQB.S.DX : 86.240 (+1.58%)
WDC : 75.77 (-1.11%)
EA : 139.33 (-0.14%)
AMD : 162.21 (+1.72%)
JSPR : 22.70 (+3.13%)
TSHA : 2.24 (+3.46%)
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies

REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.70 (+3.13%)
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...

JSPR : 22.70 (+3.13%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 26.32
2nd Resistance Point 24.91
1st Resistance Point 23.80
Last Price 22.70
1st Support Level 21.28
2nd Support Level 19.87
3rd Support Level 18.76

See More

52-Week High 31.01
Last Price 22.70
Fibonacci 61.8% 20.69
Fibonacci 50% 17.51
Fibonacci 38.2% 14.32
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar